Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease Â
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
Browsing Tag